Research progress of natural products for the treatment of ischemic stroke

Jiaxin Li1,2, Tingting Zhao3,4, Hanzi Qiao3, Yanling Li1, Mengyao Xia1, Xiaoyu Wang5, Chuanguo Liu4, Tingting Zheng1, Renjie Chen2, Yicheng Xie2, Jibiao Wu4, Xia Wei6, Jun Li2,3, Yu Feng1*, Peng Sun4†

1 School of Pharmacy, Shandong University of Traditional Chinese Medicine, 250355 Jinan, Shandong, China
2 College of Foreign Languages, Shandong University of Traditional Chinese Medicine, 250355 Jinan, Shandong, China
3 The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, 510006 Guangzhou, Guangdong, China
4 Innovation Research Institute of Chinese Medicine, Shandong University of Traditional Chinese medicine, 250355 Jinan, Shandong, China
5 The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310030 Hangzhou, Zhejiang, China
6 Shandong Institute for Food and Drug Control, 250101 Jinan, Shandong, China
*Correspondence: sunpeng@sduetcm.edu.cn (Peng Sun); fyshandong@163.com (Yu Feng); 13573756821@163.com (Jun Li)
†These authors contributed equally.

DOI: 10.31083/j.jin2101014

This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Submitted: 31 May 2021 Revised: 2 July 2021 Accepted: 22 September 2021 Published: 28 January 2022

Stroke is a leading cause of death and disability worldwide. The incidence rate of stroke has been increasing due to the aging population and lifestyle changes. At present, the only drug approved by the US Food and Drug Administration (FDA) for the treatment of ischemic stroke is tissue plasminogen activator (t-PA), but its clinical application is greatly limited because of its narrow time window and bleeding risk. Natural products have a long history of being used in traditional medicine with good safety, making them an important resource for the development of new drugs. Indeed, some natural products can target a variety of pathophysiological processes related to stroke, including oxidative stress, inflammation and neuronal apoptosis. Therefore, the development of high-efficiency, low-toxicity, safe and cheap active substances from natural products is of great significance for improving the treatment alternatives of patients with stroke. This article reviews the neuroprotective effects of 33 natural compounds by searching recent related literature. Among them, puercarin, pinocembrin, quercetin, epigallocatechin-3-gallate (EGCG), and resveratrol have great potential in the clinical treatment of ischemic stroke. This review will provide a powerful reference for screening natural compounds with potential clinical application value in ischemic stroke or synthesizing new neuroprotective agents with natural compounds as lead compounds.

Keywords
Natural products; Ischemic stroke; Mechanism

1. Introduction

Stroke is a major cause of death and disability in the world, often occurring in elderly patients [1]. There are two main types of stroke: ischemic (IS) and hemorrhagic stroke (HS). Among these, IS accounts for 80% of all cases of stroke and is caused by a blood clot in a cerebral artery. HS can be divided into intracerebral hemorrhage and subarachnoid hemorrhage and accounting for approximately 20% of the total number of stroke cases [2, 3]. With unhealthy dietary patterns, increased prevalence of high blood pressure and an aging population, the incidence rate of stroke has been increasing over recent years, bringing a heavy burden to society, families and individuals, therefore becoming a global public health issue [4, 5].

At present, the two therapeutic strategies for stroke are reperfusion and neuroprotection [6]. Reperfusion includes mechanical thrombectomy and thrombolytic therapy. However, due to this short time window of reperfusion therapy, most patients do not receive effective treatment in time. In addition, thrombolytic therapy also has the risk of reperfusion injury and bleeding, with poor long-term efficacy [7, 8]. The development of neuroprotective drugs mainly includes calcium channel antagonists, free radical scavengers, glutamate antagonists and cell membrane stabilizers, all of which are currently in the experimental stage [9]. Therefore, the characterization of novel drugs that protect against ischemic and neuronal damage is an important task at present.

Natural products have received extensive attention in recent years as a valuable resource bank for drug discovery due to their rich resources and long history of clinical application [10]. Indeed, many natural compounds against stroke have been found. They have a significant role in the early intervention of stroke, reducing adverse reactions, thus becoming potentially effective for the prevention and treatment of stroke [11, 12]. Some natural compounds can simultaneously target multiple cell signaling pathways to regulate cell function. Considering the complexity of stroke pathophysiology, multi-target strategy should be more effective for the treatment of ischemic stroke [13]. In this paper, the mechanism of different natural products in the treatment of stroke was reviewed to provide a reference for further development of drugs for the prevention and treatment of stroke.
2. Methodology

A systematic literature search through 2000–2021 was performed in Google Scholar, PubMed, and a Scientific Direct Database to identify relevant studies. We used natural compounds, phytochemicals, polyphenols, flavonoids, quercetin, kaempferol, curcumin and other search terms in the full text options, and combined stroke, cerebrovascular accident, cerebral ischemia, and ischemic stroke. The titles and abstracts were scanned to exclude any studies that were clearly irrelevant. We read the full texts of the remaining articles and classified the compounds according to their chemical structures.

3. Pathological mechanism of stroke

Stroke is a series of complicated pathophysiological reactions caused by ischemia and hypoxia. It is currently believed that energy metabolism disorders, cytotoxic effects of excitatory amino acids, oxidative stress injury, inflammation and apoptosis are the main mechanisms that cause neuronal death in focal ischemic areas of the brain and lead to IS [14].

Cerebral artery occlusion leads to the decrease of cerebral blood flow, the insufficiency of oxygen and glucose supply, the disorder of energy metabolism in the brain, and the mismatch between energy requirements and availability of neurons, glial cells and endothelial cells. Anoxic depolarization and decreased glutamate reuptake activity lead to the increase of extracellular glutamate level, activation of glutamate receptor, promotion of the influx of calcium ions into cells, mitochondrial dysfunction and a series of signal events such as the activation of free radicals and proteases, and neuronal apoptosis. This process has been termed excitotoxicity. Excessive extracellular excitatory amino acids can inhibit the absorption of cysteine by oligodendrocytes, resulting in dysfunction of oligodendrocytes. Blood-brain barrier dysfunction and release of signaling molecules (for example, cytokines) from microglia lead to an inflammatory response. Inflammatory response promotes the release of inducible nitric oxide synthase (iNOS) from neutrophils, leading to the increase of nitric oxide level. Activated microglia can increase the expression of NADPH oxidase, induce ROS production, cause oxidative stress and further damage.

3.1 Disturbance of energy metabolism in the brain

The disturbance of energy metabolism in the brain is a direct factor that contributes to brain injury in the early stages of IS. The brain tissue is the most oxygen-consuming in the body, therefore ischemia can easily disturb energy metabolism, reduce blood flow, limit the supply of oxygen and glucose, and reduce the production of ATP in mitochondria [15, 16]. ATP deficiency leads to the inhibition of ATP-dependent Na⁺/K⁺-ATP pump and Ca²⁺-ATP pump on the cell membrane as well as Na⁺ influx and K⁺ efflux, resulting in the depolarization of the nerve cell membrane, excessive Ca²⁺ influx, and activation of phospholipases and membrane proteases. Ultimately, these reactions will damage the cell membrane, induce swelling and necrosis of the brain tissue, and eventually culminate in irreversible brain damage [17].

3.2 Toxic effects of excitatory amino acids (EAA)

Glutamic acid (Glu) and aspartic acid (Asp) are the two main excitatory amino acid transmitters in the central ner-
vous system, of which Glu is the most abundant in the brain and is mainly distributed in the cortex and hippocampus [18, 19]. When the blood supply to the brain is insufficient, Glu is released in large quantities from presynaptic nerve endings, decreasing the ability of neurons and astrocytes to absorb Glu, which will disrupt the dynamic balance of Glu synthesis and decomposition, uptake and release. Glu accumulates in the synaptic space and over activates its receptor, which can cause a series of reactions such as calcium overload, increased production of nitric oxide, and generation of free radicals, which are highly toxic to the central nervous system, exerting an improvisational neurotoxic effect, namely excitotoxic effects [20, 21]. In addition, excessive extracellular EAA can inhibit the absorption of cysteines by oligodendrocytes, thereby reducing the synthesis of glutathione and damaging to oligodendrocytes [22].

3.3 Oxidative stress

Upon cerebral ischemia, the mitochondrial respiratory chain is damaged and ATP synthesis is reduced, which is accompanied by the excessive generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) [23]. In addition, activated microglia can increase the expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, inducing the generation of ROS [24, 25]. ROS has been reported to accumulate in ischemic tissue; its strong oxidation ability leads to the peroxidation of lipids, proteins and unsaturated fatty acids on the basement membrane and destroys the blood-brain barrier (BBB), ultimately causing irreversible damages on nucleic acid and carbohydrate metabolism [26, 27]. Oxidative stress also indirectly affects the permeability of the BBB by promoting the cytoskeleton reorganization, regulating the expression and distribution of tight junction proteins, affecting the expression and activity of matrix metalloproteinases, and promoting the synthesis of inflammatory factors. In the ischemic core, severe oxidative stress can lead to cell necrosis by degrading key cell components, while in the ischemic penumbra, oxidative stress activates NF-κB and MAPK signaling pathways to induce apoptosis.

3.4 Inflammation

The inflammatory response after cerebral ischemia plays an important role in the occurrence and development of IS, and a variety of immune cells and inflammatory cytokines participate in this process. During cerebral ischemia, activated astrocytes and microglia produce tumor necrosis factor-α (TNF-α), platelet activating factor (PAF), interleukin-1β (IL-1β), interleukin-6 (IL-6) and Interferon-γ (IFN-γ) [28-30]. On the one hand, these inflammatory cytokines recruit immune cells, promote signal cascade reactions, increase the production of stimulating signals such as free radicals, and chemokines, and aggravate the inflammatory response. However, on the other hand, inflammatory cytokines induce endothelial cells, astrocytes, microglia, monocytes and macrophages to synthesize matrix metalloproteinases such as matrix metalloproteinase (MMP)-2 and MMP-9, thereby destroying the basement membrane and tight junction proteins. This process increases the permeability of the BBB, and can cause cerebral edema, cerebral hemorrhage and neuronal injury [31]. After ischemic injury, the expression of inflammation-related genes BRAHMA (BRM), IκB (also known as NFκB inhibitor), FOXL1 and ITIH-5 in the stroke vasculome is upregulated, which promotes and aggravates the progress of stroke [32].

3.5 Neuronal apoptosis

Within a few hours after cerebral ischemia, dysfunctional energy metabolism, excitotoxicity of EAA, free radical damage and inflammatory immune effects will eventually induce neuronal cell death or apoptosis around the infarcted area or ischemic penumbra [33]. According to different forms of activation, apoptosis can be divided into the exogenous death receptor signaling pathway and endogenous signaling pathway, involving the activation of a variety of genes and proteins. In the endogenous pathway, the protein Bax forms oligomeric channels on the mitochondrial membrane, leading to the outflow of cytochrome c, which activates caspase 3, and ultimately removes cytoskeletal proteins and induces DNA cleavage [34-36]. As an important tumor suppressor protein and transcription factor, p53 can directly induce the expression of apoptotic proteins and genes under ischemia and hypoxia [37]. Neuronal death caused by ischemia commonly results in cell necrosis and apoptosis. Lack of oxygen induces the opening of calcium channels, and this large influx of Ca^{2+} regulates the expression of the protein Bid in the apoptotic pathway by activating calpain, and finally promoting the activation of the apoptotic pathway [38]. After focal ischemia-reperfusion injury, irreversible damage occurs in the ischemic center, while the neuronal apoptosis that occurs in the ischemic penumbra is reversible. Therefore, reducing neuronal apoptosis in the ischemic penumbra is an effective method for the treatment of stroke [39].

3.6 Other mechanisms

The blood-brain barrier (BBB) plays a vital role in regulating the trafficking of fluid, solutes and cells at the blood-brain interface and maintaining the homeostatic microenvironment of the CNS [40]. Pathological mechanisms such as inflammation and oxidative stress caused by cerebral ischemia and hypoxia can change the permeability of the BBB, resulting in the permeability towards water molecules and ions, which can form brain edema [41]. In addition, the expression of aquaporin 4 (AQP4) on the astrocyte foot process is up-regulated after cerebral ischemia-reperfusion, which can also allow excess water to accumulate in the brain [42, 43]. As a serious complication of stroke, cerebral edema can lead to higher intracranial pressure, compression of brain tissue, obstruction of cerebrospinal fluid circulation and blood flow, aggravating ischemia and edema, thus forming a vicious cycle [44, 45].

Volume 21, Number 1, 2022 3
4. Natural products for ischemic stroke

Many natural compounds that can treat stroke have been well studied (Figs. 2 (Ref. [46–91]), 3 (Ref. [92–96]), 4 (Ref. [97–101]), 5 (Ref. [102–104]), 6 (Ref. [105, 106]), 7 (Ref. [107–111])). We reviewed and summarized them for future drug discovery and application (Table 1, Ref. [46, 49, 52–54, 56, 58–63, 66, 68–70, 72–74, 76, 77, 79–81, 83, 85, 87, 90, 91, 94–98, 100, 102–111]).

4.1 Polyphenols

Polyphenols exist in many medicinal and edible plants, and possess a wide range of beneficial effects against atherosclerosis, brain dysfunction, stroke and cardiovascular diseases [112]. Polyphenols are molecules chemically characterized by the presence of at least one aromatic ring with one or more hydroxyl groups attached [113]. According to its chemical structure, polyphenols can be divided into flavonoids, lignans, stilbenes, curcuminooids and so on [2].

4.1.1 Flavonoids

Bioflavonoids are well-known antioxidants with neuroprotective effects. For instance, puerarin is the main active component of Puerariae Lobatae Radix and can regulate neuronal autophagy of rats subjected to cerebral ischemia-reperfusion injury by activating the AMPK-mTOR-ULK1 signaling pathway [46]. Puerarin treatment was shown to significantly reduce neuronal autophagy in the infarct penumbra of middle cerebral artery occlusion (MCAO) rats, and reduced cerebral infarction volume, cerebral edema and neurological deficits [47]. Meta analysis of 35 randomized controlled trials showed that puerarin injection can improve neurological deficit and reduce blood viscosity in patients with cerebral ischemia, and its clinical effective rate is better than aspirin [48].

Pinocembrin (PCB) is a natural flavonoid found in propolis, but also found in pepper and compositae. Administration of PCB 5 minutes before t-PA can significantly reduce ischemic BBB injury and cerebral infarction volume, reduce cerebral edema, improve survival rate, and extend the time window of t-PA treatment [49]. Other studies have shown that PCB can reduce the protein expression levels of light chain 3-II (LC3II) and Beclin1 in the hippocampal CA1 region of rats subjected to brain ischemia-reperfusion injury, increasing the level of p62, alleviating neuronal injury and cognitive decline, and reducing autophagy induced by autophagy inducer rapamycin (RAPA) [50]. Given its significant efficacy in cerebral ischemia, pinocembrin has been approved by China Food and Drug Administration (CFDA) as a new treatment drug for ischemic stroke and is currently in progress of phase II clinical trials [51].

Baicalin is a natural flavonoid found in the dried root of Scutellaria baicalensis Georgi. Treatment with baicalin can reduce the levels of peroxynitrite anion (ONOO-) in ischemic brain tissue, inhibit the activation of MMP-9 and reduce the expression of AQP4 in the brain. Baicalin combined with t-PA can expand the therapeutic window of t-PA, reduce mortality, alleviate BBB injury and brain edema. Moreover, this flavonoid can be used as a potential candidate for t-PA combination therapy [52]. Baicalin also decreased intracellular calcium concentration and phosphorylation of Ca2+/calmodulin-dependent protein kinase II (CaMKII) in hippocampal neurons induced by oxygen-glucose deprivation (OGD), thus reducing the apoptosis of hippocampal neurons and SH-SY5Y cells [53].

Quercetin is a flavonol widely distributed in flowers, leaves, and fruits of different species of plants. It is an active ingredient in traditional Chinese medicines such as Bu-puerariae lobatae DC., Ginkgo biloba Linn. and Folium Mori. Quercetin treatment can down-regulate the expression of caspase-3 and poly ADP-ribose polymerase (PARP), reduce the cerebral infarction volume of focal cerebral ischemia animal models, decrease neuronal apoptosis, inhibit the activity of myeloperoxidases (MPO) in ischemic brain tissue and reduce the nerve injury caused by oxidative stress [54, 55]. In addition, quercetin is neuroprotective due to its modulation of paralbumin expression during ischemic brain injury [56]. 4-methylcatechol is a human intestinal metabolite of quercetin, which is an effective platelet inhibitor. It has better curative effect than the commonly used antiplatelet drug acetylsalicylic acid, which supports its application in the prevention of thrombotic stroke [57].

Eriodictyol is a flavonol isolated from Dracauphalium rupestre Hance. In a rat permanent middle cerebral artery occlusion (pMCAO) model, elycohol was shown to inhibit the expression of MPO, decrease the inflammatory response, and down-regulate the expression of TNF-α and inducible nitric oxide synthase (iNOS) in the ischemic cortex. This ultimately resulted in reduced infarct size and memory deficit as well as an improved motor function [58]. Eriodictyol pre-treatment can down-regulate the expression of TNF-α, IL-6, IL-10 and IL-1β in the serum and cerebral cortex of temporary MCAO (tMCAO) rats, and inhibit the expression of apoptosis-related proteins Bax and cleaved-caspase-3, indicating that eriodictyol can reduce the inflammatory response after brain injury and inhibit neuronal apoptosis and improve neurological function, which may be partly attributed to the reversal of the protective effect of autophagy [59].

Isorhamnetin is a flavonoid isolated from ginkgo, seabuckthorn and other medicinal plants. In an experimental rat model of MCAO and reperfusion, isorhamnetin was able to reduce the activities of caspase-3 and MPO, alleviate oxidative stress, improve the recovery of neuronal function, reduce brain edema, and up-regulate the expression of tight junction proteins ZO-1 and claudin-5 to protect the integrity of BBB [60].

Apigenin is a natural flavonoid that mainly exists in celery, parsley, chamomile and other plants. Apigenin can inhibit the expression of histone deacetylase (HDAC), induce the expression of brain-derived neurotrophic factor (BDNF) and synapsin I (Syn-I) mRNA as well as reduce the cognitive impairment after cerebral ischemia-reperfusion injury in nicotine.
rats [61]. Apigenin can improve the neurological function of cerebral ischemia-reperfusion rats by up-regulating the Caveolin-1/VEGF pathway, and reduce pathological changes and cerebral infarction volume, and promote the proliferation of vascular endothelial cells, thereby having a protective effect on cerebral ischemia-reperfusion injury [62].

Naringin is derived from the immature or near-ripe dry peels of rutaceae plants pomelo and grapefruit. Naringin has a strong ONOO⁻ scavenging ability and can inhibit ONOO⁻-mediated mitosis, NADPH oxidase, iNOS, NO production, and protect against ischemia-reperfusion injury [63]. In addition, naringin can reduce neuronal death and
inhibit the over activation of astrocytes and microglia after ischemic injury in tMCAO mice [64, 65]. In the OGD model of neuronal cells, naringin pretreatment can activate the PI3K/AKT pathway, improve cell viability, and inhibit the secretion of inflammatory factors such as TNF-α and IL-6 [66].

Silymarin is a natural flavonoid extracted from the dried fruit of *Silybum marianum* (L.) Gaertn, and its main components are silybin, isosilybin, silydianin and silychristin, among which silybin has the highest concentration and the strongest activity [67]. In a pMCAO rat model, silymarin was shown to inhibit apoptosis by modulating procaspase-3 level and balancing the expression of B-cell lymphoma-2 (Bcl-2) and Bax, as well as through the inhibition of autophagy by reducing the levels of LC3-II and Beclin 1, thus exerting a neuroprotective effect [68].

Sappanone A is a natural high isoflavone in the legume plant *Caesalpinia sappan* L., which has significant anti-inflammatory and antioxidant effects. Sappanone A pretreatment can down-regulate the levels of CCAAT/enhancer binding protein homologous protein (CHOP) and glucose regulatory protein 78 (GRP78) in tMCAO rats, inhibit endoplasmic reticulum stress, reduce inflammation, oxidative stress and apoptosis, and alleviate neuronal injury after cerebral ischemia-reperfusion injury [69].

Epigallocatechin-3-gallate (EGCG) is the main component of polyphenols contained in green tea. EGCG can activate PI3K/Akt/eNOS signaling pathway, down-regulate the expression of caspase-3 and Bax, increase the expression of Bcl-2, reduce neuronal apoptosis and protect against brain injury induced by pMCAO [70]. In clinical trials, EGCG supplementation during rt-PA therapy can prolong the time window of rt-PA treatment, significantly reduce the adverse
Fig. 5. Chemical structures of some representative neuroprotective quinones (Ref. [102–104]).

Fig. 6. Chemical structures of some representative neuroprotective terpenoids (Ref. [105, 106]).

Fig. 7. Chemical structures of some representative neuroprotective compounds (Ref. [107–111]).
reaction of delayed administration of rt-PA and reduce the infarct volume and destruction of BBB. The underlying mechanism of EGCG in stroke involves the downregulation of MMP-2 and MMP-9 [71]. Other studies have shown that EGCG can promote angiogenesis, increase vascular density and reduce oxidative stress in tMCAO mice, which may be related to the up regulation of Nrf2 signaling pathway [72].

4.1.2 Lignans

Lignans are plant secondary metabolites derived from the oxidative coupling of phenylpropanoids [73]. Some lignans have been suggested to have potential in the prevention of cardiovascular disease and, possibly, stroke [74]. Schizandrin A is a lignin compound isolated from Schisandra chinensis, which can inhibit autophagic death of neurons after cerebral ischemia-reperfusion injury by regulating the AMPK-mTOR pathway, increasing the survival rate of PC12 cells after OGD/R, and increase mechanistic target of rapamycin (mTOR) phosphorylation [75]. Tail vein injection of Schizandrin A can improve the neurological function of MCAO rats, reduce infarct volume, increase SOD and CAT activities, reduce ROS production, down-regulate the transcription of COX-2 and iNOS, reduce the inflammatory cytokines IL-1β, IL-6 and TNF-α, and increase the release of anti-inflammatory cytokines transforming growth factor-β (TGF-β) and IL-10 [76].

4.1.3 Stilbenes

Stilbenes are natural phenolic defence compounds occurring in a number of different plant species that possess a wide range of beneficial activities, including the capability to protect against oxidative stress [77]. Resveratrol is a polyphenolic compound found in Cassia tora Linn., Veratrum nigrum Linn., Reynoutria japonica Houtt. and other medicinal plants. Studies have shown that the protective effect of resveratrol in IS is related to the regulation of the brain-gut axis [78]. Resveratrol can regulate the balance of T-helper 17/regulatory T cells (Th17/Tregs) and T-helper 1/T-helper 2 (Th1/Th2) in intestinal lamina propria and the expression of proinflammatory cytokines (IL-17A, IL-23, IL-10, IFN-γ and IL-4) in the small intestine after MCAO. Resveratrol can also reduce the permeability of the intestinal epithelium and blood vessels, reduce the transfer of cytokines from the small intestine to the blood, and reduce neuroinflammation after stroke [79]. In addition, this polyphenol can improve the activities of glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-S-transferase (GST), superoxide dismutase (SOD) and catalase (CAT) in the penumbra cortex, restore the integrity of the cell membrane and the activity of Na⁺/K⁺ ATPase, thus reducing infarct volume and improving the neurobehavioral functions in a rat tMCAO model [80]. Stroke patients received allopathic therapy and long-term resveratrol supplementation. After 12 months, compared with patients who only received allopathic therapy, patients in the resveratrol supplement group had significantly lower blood pressure, body mass index, blood lipid parameters, and blood sugar levels. Importantly, there was no new vascular disease occurring in the patients, indicating that resveratrol as an adjuvant may play a role in the secondary prevention of stroke [81].

4.1.4 Curcuminoids

Curcumin is the main active component of Curcuma longa L., curcumin treatment can activate specific protein 1 (SP1), up-regulate the expression of peroxiredoxin 6 (PRDX6) after 24 hours of cerebral ischemia and reperfusion injury, increase the number of PRDX6-positive neurons, reduce oxidative stress and exert a neuroprotective role [82]. Curcumin can alleviate the cognitive impairment caused by bilateral common carotid arteries occlusion (BCCAO), promote the proliferation of neural stem cells, promote the differentiation maturation of newly generated neural cells into neurons, increase the expression of neurogenesis related proteins (including Ngn2, Pax6 and NeuroD 1) and up regulate Wnt/β-Catenin signaling pathway [83].

4.1.5 Other phenols

Paeonol is an active ingredient present in the root bark of Paeonia suffruticosa Andr. (Ranunculaceae) and the root or whole herb of Cynanchum paniculatum (Bunge) Kitagawa (Asclepiadaceae). Studies have shown that paeonol treatment can significantly reduce behavioral disorder, cerebral infarction volume and brain edema after 72 hours of ischemia-reperfusion injury, as well as alleviate the neuronal damage in ischemic core and boundary areas after 28 days of reperfusion [84].

Salvianolic acid B (Salb) is a water-soluble component extracted from Salvia miltiorrhiza Bge. Salb is the most abundant and bioactive compound in salvianolic acid, accounting for approximately 70% of its content [85]. In a tMCAO model, SalB was shown to improve cerebral blood flow, reduce platelet aggregation, inhibit EAA neurotoxicity, reduce free radicals and improve energy metabolism. These effects were linked with inhibition of astrocytes and microglia, to prevent brain injury and promote the recovery of the motor function after cerebral ischemia/reperfusion injury in rats [86].

Apocynin is an o-methoxyphenol compound isolated from the rhizomes of Picrorhiza scrophulariiflora Pennell. Apocynin can reduce NADPH oxidase activity and ROS production after cerebral ischemia in rats, thereby preventing the activation of glial cells, down-regulating inflammation and pro-apoptotic markers, and alleviating mitochondrial injury after cerebral ischemia injury in rats [87, 88].

Salvianolic acid A (SAA) is a water-soluble phenolic acid isolated from the roots of Salvia miltiorrhiza Bge. SAA can significantly reduce the cerebral infarct area and brain water content of tMCAO rats, reduce neurological deficits and pathological changes, and enhance the anti-inflammatory and antioxidant capacities of tMCAO rats [89]. SAA was
<table>
<thead>
<tr>
<th>Category</th>
<th>Compound</th>
<th>Origin</th>
<th>Mode of study</th>
<th>Experimental model</th>
<th>Possible mechanisms</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyphenols</td>
<td>Puerarin</td>
<td>Pueraria lobatae Radix</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>APMK-mTOR-ULK1 pathway activation</td>
<td>[46]</td>
</tr>
<tr>
<td></td>
<td>Pinocembrin</td>
<td>Propolis</td>
<td>In vivo</td>
<td>I/R injury</td>
<td>PDGF-CC/PDGFRα pathway activation; LC3II and Beclin1 up-regulation, p62 inhibition</td>
<td>[49]</td>
</tr>
<tr>
<td></td>
<td>Baicalin</td>
<td>Scutellaria baicalensis Georgi</td>
<td>In vivo, in vivo</td>
<td>tMCAO, OGD</td>
<td>ONOO⁻–MMP-9 pathway inhibition; AQP4 inhibition; p-CaMKII inhibition</td>
<td>[52, 53]</td>
</tr>
<tr>
<td></td>
<td>Quercetin</td>
<td>-</td>
<td>In vivo</td>
<td>pMCAO</td>
<td>caspase-3 and PARP inhibition; parvalbumin up-regulation</td>
<td>[54, 56]</td>
</tr>
<tr>
<td></td>
<td>Eriodictyol</td>
<td>Dracaecophalum rupestre Hance</td>
<td>In vivo</td>
<td>pMCAO, tMCAO</td>
<td>TNF-α and iNOS reduction; Bax and cleaved-caspase-3 inhibition; Bcl-2 up-regulation</td>
<td>[58, 59]</td>
</tr>
<tr>
<td></td>
<td>Isorhamnetin</td>
<td>Hippophae rhamnoides</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>caspase-3 and MPO inhibition</td>
<td>[60]</td>
</tr>
<tr>
<td></td>
<td>Apigenin</td>
<td>-</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>HDAC inhibition; BDNF and Syn-1 up-regulation; Cavelolin-1/VEGF pathway activation</td>
<td>[61, 62]</td>
</tr>
<tr>
<td></td>
<td>Naringin</td>
<td>Citrus kauaiensis</td>
<td>In vitro, in vivo</td>
<td>OGD/RO, tMCAO</td>
<td>ONOO⁻ reduction; NADPH oxidase inhibition; iNOS and 3-NT reduction; PI3K/akt pathway activation</td>
<td>[63, 66]</td>
</tr>
<tr>
<td></td>
<td>silymarin</td>
<td>Silybum marianum (L.) Gaertn</td>
<td>In vivo</td>
<td>pMCAO</td>
<td>Bcl-2 up-regulation; Bax inhibition</td>
<td>[68]</td>
</tr>
<tr>
<td></td>
<td>Sappanone A</td>
<td>Casurinaia sappan L.</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>CHOP and GRP78 reduction</td>
<td>[69]</td>
</tr>
<tr>
<td></td>
<td>Epigallocatechin-3-gallate</td>
<td>Green Tea</td>
<td>In vivo</td>
<td>pMCAO, tMCAO</td>
<td>PI3K/Akt/eNOS pathway activation; Nrf2 pathway activation</td>
<td>[70, 72]</td>
</tr>
<tr>
<td></td>
<td>Schizandrin A</td>
<td>Schisandra chinensis</td>
<td>In vitro, in vivo</td>
<td>OGD/R, tMCAO</td>
<td>AMPK-mTOR pathway activation; AMPK/Nrf2 pathway activation</td>
<td>[73, 74]</td>
</tr>
<tr>
<td></td>
<td>Resveratrol</td>
<td>-</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>IL-17A, IL-23, IL-10, IFN-γ and IL-4 reduction; GPx, GR, GST, SOD, CAT and Na⁺ K⁺ ATPase up-regulation</td>
<td>[76, 77]</td>
</tr>
<tr>
<td></td>
<td>Curcumin</td>
<td>Curcuma longa L.</td>
<td>In vivo</td>
<td>tMCAO, BCCAO</td>
<td>SP1/Pdx6 pathway activation; Wnt/b-catenin pathway activation; Ngn2, Pax6 and NeuroD1 up-regulation</td>
<td>[79, 80]</td>
</tr>
<tr>
<td></td>
<td>Paeonol</td>
<td>Paeonia suffruticosa Andr</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>astrocytes proliferation reduction; microglial activation inhibition</td>
<td>[81]</td>
</tr>
<tr>
<td></td>
<td>Salvianolic acid B</td>
<td>Salvia miltiorrhiza Rge.</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>ROS reduction; GPAP, Iba1, IL-1β, IL-6, TNF-α and cleaved-caspase 3 reduction</td>
<td>[83]</td>
</tr>
<tr>
<td></td>
<td>Apocynin</td>
<td>Picrorhiza urupharalifaria Pennell.</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>NADPH oxidase inhibition, ROS reduction</td>
<td>[85]</td>
</tr>
<tr>
<td></td>
<td>Salvianolic acid A</td>
<td>Salviae Miltiorrhizae Bunge.</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>ONOO⁻ reduction</td>
<td>[87]</td>
</tr>
<tr>
<td>Glycosides</td>
<td>Cornin</td>
<td>Verbena officinalis L.</td>
<td>In vitro, in vivo</td>
<td>OGD, tMCAO</td>
<td>Ang1/Tie2 axis activation; Wnt/b-catenin pathways activation; PI3K-Akt-eNOS-VEGF pathway activation</td>
<td>[90, 91]</td>
</tr>
<tr>
<td></td>
<td>Astragaloside-IV</td>
<td>Astragalus membranaceus (Fisch.) Bunge.</td>
<td>in vivo</td>
<td>tMCAO</td>
<td>death receptor pathway and mitochondrial pathway inhibition; SIRT1 up-regulation; ac-MAPT and p-MAPT reduction</td>
<td>[94, 95]</td>
</tr>
<tr>
<td></td>
<td>6'-O-galloylpaeoniflorin</td>
<td>Paeonia lactiflora Pall.</td>
<td>In vitro, in vivo</td>
<td>OGD, tMCAO</td>
<td>PI3K/Akt/Nrf2 pathway activation</td>
<td>[96]</td>
</tr>
<tr>
<td>Esters</td>
<td>Andrographolate</td>
<td>Andrographis paniculata (Burm. L.) Nees.</td>
<td>In vivo</td>
<td>tMCAO</td>
<td>Nrf2-HO-1 pathway activation</td>
<td>[97]</td>
</tr>
<tr>
<td></td>
<td>Ginkgoide B</td>
<td>Ginkgo biloba L.</td>
<td>In vitro</td>
<td>OGD/R</td>
<td>Bcl-2 up-regulation; Bax inhibition</td>
<td>[98]</td>
</tr>
<tr>
<td></td>
<td>3-n-butylphthalide</td>
<td>Apium graveolens L.</td>
<td>In vivo</td>
<td>pMCAO</td>
<td>ATP degradation Inhibition</td>
<td>[100]</td>
</tr>
<tr>
<td>Category</td>
<td>Compound</td>
<td>Origin</td>
<td>Mode of study</td>
<td>Experimental model</td>
<td>Possible mechanisms</td>
<td>References</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------</td>
<td>-------------------------------</td>
<td>---------------</td>
<td>--------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Quinones</td>
<td>Tanshinone IIA</td>
<td><em>Salvia miltiorrhiza</em> Bge.</td>
<td><em>In vivo</em></td>
<td>pMCAO</td>
<td>PI3K/mTOR/HER-3 pathway activation</td>
<td>[102]</td>
</tr>
<tr>
<td></td>
<td>Chrysophanol</td>
<td><em>Rheum palmatum</em> L.</td>
<td><em>In vivo</em></td>
<td>tMCAO</td>
<td>SOD and MnSOD activation; p-eIF2α-CHOP pathway inhibition</td>
<td>[103, 104]</td>
</tr>
<tr>
<td>Terpenoids</td>
<td>Glycyrrhizin</td>
<td><em>Glycyrrhiza uralensis</em> Fisch.</td>
<td><em>In vivo</em></td>
<td>tMCAO</td>
<td>ONOO⁻/HMGB1/TLR2/MMP-9 pathway inhibition</td>
<td>[105]</td>
</tr>
<tr>
<td></td>
<td>Carvacrol</td>
<td><em>Origanum dictamum</em></td>
<td><em>In vivo</em></td>
<td>tMCAO</td>
<td>NF-κB pathway inhibition</td>
<td>[106]</td>
</tr>
<tr>
<td>Other compounds</td>
<td>trigolavine</td>
<td><em>Trigonella foenum-graecum</em> L.</td>
<td><em>In vivo</em></td>
<td>tMCAO</td>
<td>MPO inhibition</td>
<td>[107]</td>
</tr>
<tr>
<td></td>
<td>Xycycline B</td>
<td><em>Xylaria sp.</em></td>
<td><em>In vitro</em>; <em>in vivo</em></td>
<td>OGD, hypoxic-ischemic brain injury model</td>
<td>caspase-3 reduction; Bax inhibition; Bcl-2 up-regulation</td>
<td>[108]</td>
</tr>
<tr>
<td></td>
<td>Indole-3-carbinol</td>
<td><em>Brassica sp.</em></td>
<td><em>In vivo</em></td>
<td>tMCAO</td>
<td>SOD and CAT up-regulation</td>
<td>[109]</td>
</tr>
<tr>
<td></td>
<td>Ergostatrien-7,9(11),22-trien-3β-ol</td>
<td><em>Antrodia camphorata</em></td>
<td><em>In vivo</em></td>
<td>tMCAO</td>
<td>PI3K/Akt pathway activation; GSK-3 inhibition</td>
<td>[110]</td>
</tr>
<tr>
<td></td>
<td>Achyranthes bidentata polypeptide k</td>
<td><em>Achyranthes Bidentata</em> Bloom</td>
<td><em>In vitro</em>; <em>in vivo</em></td>
<td>tMCAO, OGD</td>
<td>NF-κB pathway inhibition; TF and PAI-1 and MMP-2/-9 inhibition</td>
<td>[111]</td>
</tr>
</tbody>
</table>
shown to improve the sensorimotor and persistent memory impairments caused by focal ischemia in the unilateral frontal cortex of rats, suggesting that SAA has therapeutic potential in the treatment of IS-related memory impairment [90]. In addition, SAA can inhibit the production of ONOO-, up-regulate the phosphorylation levels of protein kinase B (AKT), forkhead transcription factor (FKHR) and extracellular signal-regulated kinase (ERK), increase glucose metabolism after cerebral ischemia, reduce neurological deficits, and protect the brain from ischemia/reperfusion injury [91].

4.2 Glycosides

Cornin is an iridoid glycoside isolated from the fruits of Verbena officinalis L., which can induce angiogenesis in vitro by increasing the proliferation, invasion and lumen formation [92]. Subsequent studies confirmed that cornin can reduce BBB leakage and promote angiogenesis and functional recovery after stroke by increasing the proliferation of rat arterial smooth muscle cells (RASMC) and the expression of Wnt5a, β-catenin, cyclin D1 and angiopoietin-I (Ang1) [93].

Astragaloside IV (AS-IV), the main active component of Astragalus membranaceus (Fisch.) Bunge., was shown to exert neuroprotective effects in a rat cerebral ischemia-reperfusion injury model. It can modulate Fas, Fas ligand (FasL), caspase-8 and Bax/Bcl-2, reduce the protein levels of apoptotic cytokines Bid, cleaved caspase-3 and Cytochrome C (Cyto C), and reduce the volume of cerebral infarction and neuronal apoptosis [94]. In addition, AS-IV can up-regulate the expression of SIRT1 in tMCAO rats, reduce the levels of acetylated MAPT (ac-MAPT) and phosphorylated MAPT (p-MAPT), and improve neurological deficits after ischemia-reperfusion, indicating that AS-IV may play a neuroprotective effect by regulating the SIRT1/MAPT pathway [95].

Galloylpaeoniflorin (GPF) is an effective ingredient extracted from Paeonia lactiflora Pall. or Paeonia veitchii Lynch. GPF pretreatment can increase the levels of phosphorylated Akt and nuclear factor-erythroid 2-related factor 2 (Nrf2) in an OGDR cell model, as well as reduce the cerebral infarction volume and improve neurological deficits of rats subjected to cerebral ischemia-reperfusion injury [96].

4.3 Esters

Andrographolide is a diterpenoid lactone and it is the main active component of Andrographis paniculata (Burm. f.) Nees. By regulating the Nrf2-HO-1 signaling pathway, andrographolide can inhibit the formation of free radicals and destruction of the BBB in MCAO rats [97].

Ginkgolide B (GB) is a diterpene lactone compound isolated from Ginkgo biloba L. leaves. Pretreatment with GB was shown to down-regulate the expression of Bax, up-regulate the expression of Bcl-2, alleviate the damage of neurons and endothelial cells induced by oxygen-glucose deprivation/reoxygenation (OGD/R), and reduce the apoptosis rate of cells [98].

3-n-butylphthalide (NBP), also known as apigenin, was originally isolated from the seeds of Apium graveolens L., and was shown to protect against acute ischemic stroke [99]. NBP can inhibit the degradation of ATP and reduce the production of ATP-degradation metabolites adenosine, inosine, hypoxanthine and xanthine. Hypoxanthine and xanthine are the substrates that produce oxygen free radicals, suggesting that NBP can reduce the generation of superoxide, reduce lipid peroxidation and neuronal apoptosis [100]. NBP can down-regulate the expression of intercellular adhesion molecule-1 (ICAM-1) and protease activated receptor-1 (PAR-1) in cerebral vascular endothelial cells and improve cerebral blood flow after cerebral ischemia-reperfusion in a rat model of tMCAO and photothrombus-induced permanent cerebral ischemia [101].

4.4 Quinones

Tanshinone IIA is extracted from the dried rhizome of Salvia miltiorrhiza Bge., and is commonly used in the treatment of cerebrovascular diseases. Tanshinone IIA can promote the recovery of cerebral ischemia-reperfusion injury, increase glucose uptake and energy supply of neurons by targeting GLUT1, and reducing the expression of inflammatory factors COX-2, IL-1/β, prostaglandin E2 (PGE2) and monocyte chemoattractant protein-1 (MCP-1) [102].

Chrysophanol (CHR) is an active component extracted of Rheum palmatum L. CHR can reduce neuronal damage caused by nitric oxide, decrease the level of 3-nitrotyrosine (3-NT) and the expression of caspase-3 in ischemic brain tissue. It can also increase the activity of manganese dependent superoxide dismutase (MnSOD), interrupt the feedback circuits of ROS/RNS and SOD, and inhibit the production of ROS in ischemic brains, which indicates that CHR can alleviate the nitrification/oxidative stress injury caused by ischemia-reperfusion injury [103]. It has been shown that CHR treatment inhibits GRP78, phosphorylated eukaryotic initiation factor 2α (p-eIF2α), inhibitory kB-α (IκB-α), CHOP and caspase-12 in MCAO rats, indicating that CHR protects against ischemia-reperfusion injury by inhibiting endoplasmic reticulum stress-related neuronal apoptosis [104].

4.5 Terpenoids

Glycyrrhizin (GL), a triterpenoid isolated from the root of Glycyrrhiza uralensis Fisch., is a natural high mobility-group box 1 (HMGB1) inhibitor. In a rat model of IS, GL can reduce the expression of NADPH oxidase in the brain, inhibit the production of ONOO-, reduce the release of HMGB1, alleviate the BBB damage and neuronal apoptosis, and reduce the mortality [105].

Carvacrol is a phenolic monoterpane widely found in natural aromatic plants. In a model of focal cerebral ischemia/reperfusion injury in rats, carvacrol could inhibit the level of inflammatory cytokines and the activity of MPO, inhibit the expression of iNOS, cyclooxygenase-2 (COX-2) and nuclear NF-κB-p65 as well as increase the activity of SOD.
in ischemic cortical tissues [106]. Carvacrol can be used as a potential drug for the treatment of cerebral ischemic injury.

4.6 Other compounds

Trigonelline is a plant alkaloid extracted from the seeds of *Trigonella foenum-graecum* L., a leguminous plant. Administration of 100 mg/kg trigonelline immediately after cerebral ischemia in rats can reduce cerebral infarction, improve motor and neurological deficit scores, and significantly inhibit the expression of myeloperoxidase mediated by reduced glutathione in the cerebral cortex [107].

Xyloketal B is a natural compound isolated from mangrove fungi in the South China Sea. It can protect cortical neurons from OGD-induced cell death, reduce the volume of cerebral infarction and improve the recovery of the neural function in rats with hypoxic-ischemic brain injury [108].

Indole-3-carbinol (I3C) is a natural compound with antithrombotic activity extracted from Brassica plants. I3C can increase the levels of SOD and CAT, increase cerebral blood flow, inhibit ADP-induced platelet aggregation, and reduce the volume of ischemic cerebral infarction in tMCAO rats. In addition, I3C pretreatment shortened the length of carrageenan-induced tail thrombosis in rats, suggesting its preventive antithrombotic effect [109].

Ergostatrien-7,9(11),22-trien-3-ol (EK100) is the main active ingredient of the ethyl acetate extract of *Antrodia camphorata*, which has anti-inflammatory and anti-apoptotic effects. EK100 treatment reduced the expression of p65NF-κB and caspase-3 in the cortex around the infarcted brain area mice subjected to acute ischemic stroke. Meanwhile, EK100 increased the generation of endogenous neural stem cells (DCX+) and the expression level of Bcl2 by activating the PI3K/Akt signaling pathway [110]. The value of EK100 combined with r-tPA in the treatment of human acute ischemic stroke deserves further study.

Achyranthes bidentata polypeptide K (ABPPk) is an active ingredient isolated from *Achyranthes Bidentata* Bloom. It can reduce the oxidative damage of brain endothelial cells induced by ischemia, inhibit the expression of tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1) and NF-κB, and reduce downstream microthrombus formation. In addition, ABPPk can inhibit the infiltration of polymorphonuclear leukocytes (PMNs) in the ischemic penumbra, decrease the expression of MMP-2 and MMP-9, prevent the destruction of BBB, and improve neurological function after stroke [111].

5. Discussion

The application history of natural compounds in traditional medicine and their excellent safety make them attractive in the development of human disease therapeutics. Clues to the relationship between the intake of natural compounds and beneficial effects on stroke come from epidemiological studies. A prospective study involving 74961 participants showed that the intake of fruits and vegetables was negatively correlated with the risk of stroke, suggesting that phytochemicals in fruits and vegetables may reduce the incidence of ischemic stroke by weakening the key pathological processes leading to stroke [114]. In addition, fruit polyphenol supplements have been shown to improve the cognitive and functional recovery of patients with ischemic stroke [115]. Results from a meta-analysis considering 11 prospective cohort studies suggested that high dietary intake of flavonoids may moderately reduce the risk of stroke [116]. Different prospective studies have also examined the relationship between dietary flavonoid subclasses and stroke. Higher dietary flavonol intake has been associated with a reduced risk for stroke [117]. The increased intake of flavanones has been associated with diminished risk of brain ischemia in women [118]. In a cohort study, eating foods rich in quercetin reduced the risk of thrombotic stroke [119]. Pyrogallol, a human metabolite of EGCG in green tea, can inhibit platelet aggregation in human blood, indicating that green tea may play a protective role in brain by inhibiting platelet aggregation [57].

Neuroprotective natural compounds can inhibit the key pathogenic process of ischemic brain injury, and can be used as a powerful candidate for stroke treatment. A growing body of evidence from cell culture models and animal models of brain ischemia suggests the brain protective potential of a variety of natural compounds [120]. Human ischemic stroke is extremely diverse in its manifestations, causes, and anatomic localization, whereas an experimental ischemic stroke is highly reproducible, well controllable, and standardized, allowing more precise analysis of stroke pathophysiology and drug effects, which is an indispensable tool to study stroke [121]. However, there are differences in results between animal models of stroke and humans. The reasons for this difference are: differences in brain function and structure between humans and rodents, difficulty in controlling the time window of clinical treatment after stroke as precisely as in animal experiments and the lack of basic risk factors and pathological processes of the disease in animal models. Long-term, large-scale and well-designed clinical trials are therefore needed.

6. Conclusions

Stroke is a common clinical disease of difficult treatment that is characterized by its high morbidity, disability, and mortality. The pathogenesis of stroke is complex, and it involves the regulation of a variety of genes and signaling pathways, which ultimately lead to brain damage and dysfunction. Existing drug therapy or surgical methods have some issues, such as a narrow treatment window, high risk of complications and high failure rate.

Natural products are an important source of drug discovery, being often multi-targeted, regulating multiple pathways, and displaying potential advantages in the treatment of stroke. Natural products can play a neuroprotective role by intervening in excitotoxicity, oxidative and nitrifying stress, inflammation and other pathological processes, thus deserv-
ing further investigation. The combination of natural products and other treatment methods can synergize to prolong the treatment time window and reduce stroke complications. Therefore, future research should explore the use of natural products in the treatment of stroke. Moreover, it is also necessary to conduct pharmacokinetics, pharmacodynamics and toxicological studies of natural products. Finally, the potential interaction of natural products with rt-PA should be examined before being used as a combination therapy.

Abbreviations

FDA, Food and Drug Administration; t-PA, tissue plasminogen activator; IS, ischemic; HS, hemorrhagic stroke; iNOS, inducible nitric oxide synthase; Glu, glutamic acid; Asp, aspartic acid; RNS, reactive nitrogen species; NADPH, nicotinamide adenine dinucleotide phosphate; BBB, blood-brain barrier; TNF-α, tumor necrosis factor-α; PAF, platelet activating factor; IL-1β, interleukin-1β; IL-6, interleukin-6; IFN-γ, Interferon-γ; MMP, matrix metalloproteinase; AQP4, aquaporin 4; MCAO, middle cerebral artery occlusion; PCB, Pinocembrin; LC3II, light chain 3-II; RAPA, Amines target of RAPA; COX-2, cyclooxygenase-2; TGF-β, transforming growth factor-β; Th17/Tregs, T-helper 17/regulatory T cells; Th1/Th2, T-helper 1/T-helper 2; GPx, glutathione peroxidase; GR, glutathione reductase; GST, glutathione-S-transferase; SOD, superoxide dismutase; CAT, catalase; RDX6, peroxiredoxin 6; BCCAO, bilateral common carotid arteries occlusion; SalB, Salvianolic acid B; AAA, Atherosclerosis; Ang1, angiopoietin-1; AS-IV, Astragaloside IV; Cyto C, Cytochrome C; ac-MAPT, acetylated MAPT; p-MAPT, phosphorylated MAPT; GPF, Galloylpaeoniflorin; Nrf2, nuclear factor-erythroid 2-related factor 2; GB, Ginkgolide B; Bcl-2, B-cell lymphoma-2; CHOP, CCAAT/enhancer binding protein homologous protein; GRP78, glucose regulatory protein 78; EGCG, Epigallocatechin-3-gallate; OGD/R, oxygen-glucose deprivation/reoxygenation; mTOR, mechanistic target of RAPA; COX-2, cyclooxygenase-2; TGF-β, transforming growth factor-β; Th17/Tregs, T-helper 17/regulatory T cells; Th1/Th2, T-helper 1/T-helper 2; GPx, glutathione peroxidase; GR, glutathione reductase; GST, glutathione-S-transferase; SOD, superoxide dismutase; CAT, catalase; RDX6, peroxiredoxin 6; BCCAO, bilateral common carotid arteries occlusion; SalB, Salvianolic acid B; AAA, Atherosclerosis. 

Funding

This study was supported by the National Natural Science Foundation of China (NSFC, Nos. 81873719 and 81303074), National Health Commission of the people’s Republic of China (No. 2011ZX09301064002) and Youth Innovation Team of Shandong University of Traditional Chinese Medicine.

Conflict of interest

The authors declare no conflict of interest.

References


Hongyun H, Tao G, Pengyue Z, Liqiang Y, Yihao D. Puerarin pro-vides a neuroprotection against transient cerebral ischemia by at-


Fodor K, Tit DM, Pasca B, Buxtea C, Uivarosan D, Endres L, et al. Long-Term Resveratrol Supplementation as a Secondary Prophy-


Yang X, Song D, Chen L, Xiao H, Ma X, Jiang Q, et al. Curcumin promotes neurogenesis of hippocampal dentate gyrus via Wnt/β-


Kapoor M, Sharma N, Sandhri R, Nehru B. Effect of the NADPH oxido-

bined NADPH and the NOX inhibitor apocynin provides greater anti-

Feng S, Aa N, Geng J, Huang J, Sun R, Ge C, et al. Pharmacoki-


Yin F, Zhou H, Fang Y, Li C, He Y, Lu L, et al. Astragaloside IV a-
leviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochon-

Sin F, Zhou H, Fang Y, Li C, He Y, Lu L, et al. Astragaloside IV a-
leviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochon-


drogropholide stimulates p38 mitogen-activated protein kinase-
nuclear factor erythroid-2-related factor 2-heme oxygenase 1 sig-

Yang X, Zheng T, Hong H, Cai N, Zhou X, Sun C, et al. Neuropro-


Wang J, Tong H, Wang X, Wang X, Wang Y. Tanshinone IIA alleviates the damage of neurocytes by targeting GLUT1 in is-

Zhao Y, Huang Y, Fang Y, Zhao H, Shi W, Li J, et al. Chryso-
phanol attenuates nitrosative/oxygenative stress injury in a mouse model of focal cerebral ischemia/reperfusion. Journal of Pharma-

Zhao Y, Fang Y, Zhao H, Li J, Duan Y, Shi W, et al. Chryso-

logicalOutcome in Ischemic Stroke with Delayed Thromboly-

Li Z, Hua C, Pan X, Fu X, Wu W. Carvacrol Exerts Neuropro-

neline therapy confers neuroprotection by reduced glu-


Paliwal P, Chauhan G, Gautam D, Dash D, Patne SUC, Krish-
namurthy S. Indole-3-carbinol improves neurobehavioral symp-
toms in a cerebral ischemic stroke model. Naunyn-Schmiedebergs

Wang YH, Chern CM, Liou KT, Kuo YH, Shen YC. Ergostatrien-7, 9 (11), 22-trien-3-ol from Antrodia camphorata ameliorates ischemic stroke brain injury via downregulation of p53NF-κB and caspase 3, and activation of Akt/GSK3/catenin-


Tresserra-Rimbau A, Arranz S, Eder M, Vallverdu-Queralt A. Di-

Tresserra-Rimbau A, Lamuela-Raventos RM, Moreno JJ. Polyphenols, food and pharma. Current knowledge and direc-


